Sources: Top 10 Arthritis-related Events of 2008
1) HOUSE PASSES LANDMARK ARTHRITIS LEGISLATION
2) EARLY, AGGRESSIVE THERAPY BEST FOR RA
Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008; 58: 1310-17.
Van Vollenhoven R, Ernestam S, Geborek P, et al. In early RA, patients with a good initial response to MTX monotherapy continue to have excellent clinical outcomes during the first year of therapy. Abstract presented at American College of Rheumatology Annual Scientific Meeting, October 2008.
Van der heijde D, Landewe R, Sharp JT, et al. Initial combination therapy with adalimumab and methotrexate leads to better long-term inhibition of radiographic progression in early RA: 5-year results of the PREMIER trial. Abstract presented at American College of Rheumatology Annual Scientific Meeting, October 2008.
Breedveld FC, Kavanaugh A, van Riel P, et al. Initial combination therapy with adalimumab and methotrexate sustains clinical remission and response for early RA patients treated through year 5. Abstract presented at American College of Rheumatology Annual Scientific Meeting, October 2008.
Emery P, Genovese M, van Vollenhoven R, et al. Adalimumab inhibited radiographic progression more effectively than methotrexate in early RA patients who had achieved a normal C-reactive protein concentration. Abstract presented at American College of Rheumatology Annual Scientific Meeting, October 2008.
3) KINASE INHIBITORS PROMISING TREATMENT FOR RA
Weinblatt M, Kavanaugh A, Grossbard E, for the TASKI-1 Trial. Treatment of rheumatoid arthritis (RA) with a Syk kinase inhibitor: A 12 week randomized placebo controlled study. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
Kremer J, Cohen S, Wilkinson B, et al. The oral Jak inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
4) ARTHRITIS HAMPERS ACTIVITY IN ADULTS WITH DIABETES
5) BIOLOGIC THERAPIES BENEFIT CHILDREN WITH JA
Abbott Receives Approval for Humira for Polyarticular Juvenile Idiopathic Arthritis
US Food & Drug Administration Approves Orencia for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis
Abatacept in Children with Juvenile Idiopatchic Arthritis
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
6) CARDIOVASCULAR RISK HIGH IN ARTHRITIS
van Halm VP, Peters MJL, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross sectional study. The CARRÉ Investigation. Ann Rheum Dis. Published Online First: 12 August, 2008.
Basilico FC, Sweeney G, Losina E, et al. Risk factors for cardiovascular complications following total joint replacement surgery. Arthritis & Rheumatism 2008;58:1915-1920.
7) STATE ARTHRITIS PROGRAMS ENHANCED
Physical Activity. The Arthritis Pain Reliever
8) IMMUNE SYSTEM AGES EARLY IN ARTHRITIS
These findings provide an important clue to the pathogenesis of autoimmune diseases such as rheumatoid arthritis. Premature aging of the immune system and disturbed T cell numbers and functions would appear to play an important, fundamental role in the immune abnormalities that occur in these diseases.
Colmegna I, Diaz-Borjon A, Fujii H, et al. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008; 58: 990-1000.
Prelog M, Schwarzenbrunner N, Sailer-Hock M, et al. Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 2153-62.
9) GINGIVITIS AND RA LINKED
Hitchon CA, Chandad F, Ferucci E, et al. Antibodies to P. gingivalis are associated with anti-citrullinated protein antibodies (ACPA) in RA patients and their relatives. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
Mikuls TR, Pyne JB, Reinhardt RA, et al. Immunity to the oral pathogen, Porphyromonas gingivalis (P. gingivalis), in subjects with rheumatoid arthritis and periodontitis. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
Dissick A, Redman RS, Jones M, et al. Increased periodontal disease in US veterans with rheumatoid arthritis. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
Bingham CO III, Giles JT, Jones PE, Bathon JM, Bartlett SM. High prevalence of moderate to severe periodontal disease in rheumatoid arthritis patients. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, November 2007.
Bingham CO III, Bartlett SJ, Hildebrant M, et al. Periodontal disease symptoms are independently associated with rheumatoid arthritis disease activity. Abstract presented at the American College of Rheumatology Annual Scientific Meeting, October 2008.
Pischon N, Pischon T, Kroger J, et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontology 2008; 79: 979-986.
10) NEARLY HALF OF AMERICANS WILL DEVELOP OA
Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum (Arthritis Care Res) 2008; 59: 1207-13
